Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

BACKGROUND: Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, could result in premature treatment termination. The randomiz...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Haddad, Robert, Concha‐Benavente, Fernando, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Kasper, Stefan, Vokes, Everett E., Worden, Francis, Saba, Nabil F., Tahara, Makoto, Jayaprakash, Vijayvel, Lynch, Mark, Li, Li, Gillison, Maura L., Harrington, Kevin J., Ferris, Robert L.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771504/
https://ncbi.nlm.nih.gov/pubmed/31246283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32190
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires